All News

Without company or insurance contracts, controlled medication prices reduce burden on patients.

The National Institute of Health’s grant funds a phase 2 clinical trial of doxycycline in a large group of individuals with the 2 conditions who are smokers or used to smoke.

Steve Simske, PhD, discusses his research investigating how the occurrence of discrimination in biology can act as an agnostic analogy for discrimination in humans’ social environments.

In 10 states, the data showed more than 26% of women had limited accessibility to mammography, primarily in the Rocky Mountains and the South.

Participants who survived Hodgkin lymphoma as children showed signs of being biologically older than their peers, with a heightened risk of cognitive problems.

The phase 2 GO29781 study showed that 80% of patients who had received at least 2 prior therapies achieved durable response rates with mosunetuzumab-axgb treatment.

Jawad Saleh, PharmD, BSPharm, BCCCP, BCPS, clinical manager of Pharmacy Services at the Hospital for Special Surgery, discusses how pharmacists can treat postoperative nausea and vomiting.

Can a brand name manufacturer be held liable for damages caused by a drug product manufactured by another firm?

Results show possible impact of using Janssen Pharmaceuticals’ ibrutinib in the front-line setting, providing additional data on chronic lymphocytic leukemia therapies.

Intravenous tocilizumab (Actemra; Genentech) has been approved for the treatment of COVID-19 in individuals who are hospitalized and receiving systemic corticosteroids and supplemental oxygen.

The FDA approved lenacapavir, which is the first approval of a drug in a new class of antiretrovirals for the treatment of HIV-1 called capsid inhibitors.

The FDA's approval includes the group indication for all current and future EGFR TKIs, including erlotinib, osimertinib, and gefitinib.

HOPA DEI Committee chair Kamakshi Rao, PharmD, BCOP, FASHP, noted that on the DEI journey ahead, the oncology pharmacist should be front and center as part of the treatment team.

But many patients pay more than necessary because of PBMs, patent abuses, IQVIA data shows.

The analysis found that individuals in underserved communities were as much as 34% less likely to be vaccinated against COVID-19.

Calcitriol may offer protection from the harmful effects of the chemical in drinking water, analysis shows.

The protein is vitally important and could be a prognostic indicator and potential therapeutic target.

TD2 remission is defined as a hemoglobin A1C level of less than 6.5% at least 1 year after stopping medication, investigators say.

Alex Barker founded The Happy PharmD to provide career coaching and career development classes, and since 2017, the company has helped over 1,500 pharmacists.

Significant advancements have changed the treatment landscape and clinical practice procedures.

From newsworthy moments to groundbreaking research, these are the most popular articles in the cholangiocarcinoma space, published on Pharmacy Times® during 2022.

A controlled substances diversion prevention program (CSDPP) that aligns with the revised ASHP guidelines is critical to ensure patients are protected from occurrences of drug diversion.

An anti-cancer vaccine that is now in clinical trials shows promise as a preventative agent. However, experts are unsure when it will be widely available.

In addition to ongoing staffing patterns and new technology, an expert said pharmacies will have to adapt to new ways of educating students and staff.

Recommendations for the management of bile duct cancer benefit authorities, patients, and physicians, but investigators say more research is needed.

The FDA granted Priority Review to both applications and set a Prescription Drug User Fee Act goal date for each application of April 21, 2023.

Survey shows pharmacies could implement more point-of-care testing and have a large pool of willing participants.

Lions and tigers and zebras oh my! Expert says precision medicine helps identify unique “zebras” (cancers), but it is increasingly difficult to keep up with new treatment indications across a broad range of cancers.